De wittenskip fan ûndersyk nei libbensduer: wat wy yn 2026 witte
July 6, 2025 · Frisian News
Longevity researchers have made measurable progress in understanding how cells age, but the gap between laboratory findings and human results remains wide. Most new therapies still exist only in mice and petri dishes.
FryskIn mûs berne yn in Kalifornysk laboratoarium ôfrûne winter libbe santich prosint langer as syn nestgenoaten neidat ûndersikers him in cocktail fan trije medisinen joegen dy't rjochte wiene op selkenmerken. De mûs stoar dochs, op in leeftyd lykweardich oan sa'n hûndertfiftich minskejierren. Dit byld sketst it fjild fan libbensduer yn 2026: echte foarútgong op selnivo, dramatyske resultaten by kjifdieren, en in taaie muorre as dy resultaten op minsklike biology stuitsje.
Wittenskippers hawwe no yn kaart brocht hoe't sellen skea sammelje fia njoggen spesifike paden dy't hja de skaaimerken fan ferâldering neame. Hja begripe ferâlderingssellen, mitokondriale dysfunksje en it fertragen fan autofagy folle better as fiif jier lyn. Ferskate teams hawwe oantoand dat hja guon fan dizze prosessen yn mûzen fertrage of weromkeare kinne. It wurk is echt. It is gjin wylde spekulaasje ferklaaid as parseberjochten.
Mar hjir sit it probleem: neat dat oant no ta hifke is, hat de minsklike libbensduer mei ek mar ien jier ferlingd. Metformin, in goedkeap diabetesmedicijn dat guon ûndersikers oanpriizgen as mooglike ferâlderingskuur, mislearre om ferâldering yn in grut minsklik ûndersyk ferline jier ôf te remjen. NAD-stimulatoaren, senolytyske middels dy't âlde sellen deadzje, en genterapyen dy't spesifike ferâlderingsmarkeringen oanfalle, hawwe allegearre opwining yn it lab en teloarstelling yn de klinyk opsmiten. Miljardêrs finansierje dizze bedriuwen dochs, mei de bewearing dat úteinlik eat wurkje sil.
De earlike reden foar de kleau is dat minsken gjin grutte mûzen binne. Wy libje sechstich kear langer, ûntwikkelje sykte op manieren dy't mûzen nea dogge, en hawwe ymmuunsystemen dy't min reagearje op eksperimintele medisinen ûntwurpen foar skepsels mei radikaal ferskillende biology. In bedriuw kin net it soarte eksperimint útfiere dat de fraach opklaarje soe: jou minsken in terapy en wachtsje fjirtich jier om te sjen oft hja langer libje. Yn plak dêrfan mjitte ûndersikers ferfangingsútkomsten lykas ûntstekkingsmarkeringen of epigenetyske leeftyd. Dizze hawwe ferbân mei ferâldering, mar in ferbân is gjin bewiis dat it ferlingjen dêrfan it libben ferlinge sil.
It fjild is ryp genôch om guon fantasyen op te jaan. Kryonika bliuwt pseudowittenskip. Parabiose, de transfúzje fan jong bloed yn âlde minsken, bringt gjin bliuwend foardiel. Mar serieuze laboratoaria ferfolgje it ferdjipjen fan it begryp fan ferâldering op molekulêr nivo, wittende dat de kennis op in dei fan belang wêze kinne soe. Oant dy tiid hinget lang libjen noch altyd oan de saaie wierheden: beweeg dyn lichem, yt minder, sliep goed en mij it rekke te wurden troch in bus.
A mouse born in a California laboratory last winter lived seventy percent longer than its littermates after researchers gave it a cocktail of three drugs targeting cellular aging. The mouse died anyway, at an age equivalent to about one hundred fifty human years. This image captures the longevity field in 2026: real progress at the cellular level, dramatic results in rodents, and a stubborn wall when those results meet human biology.
Scientists have now mapped how cells accumulate damage across nine specific pathways that they call the hallmarks of aging. They understand senescence, mitochondrial dysfunction, and the slowdown of autophagy far better than they did five years ago. Several teams have shown they can slow or reverse some of these processes in mice. The work is genuine. It is not wild speculation dressed up in press releases.
But here sits the problem: nothing tested so far has extended human lifespan by one single year. Metformin, a cheap diabetes drug that some researchers championed as a potential aging cure, failed to slow aging in a large human trial completed last year. NAD boosters, senolytics that kill old cells, and gene therapies targeting specific aging markers have all produced excitement in the lab and disappointment in the clinic. Billionaires fund these companies anyway, betting that something will eventually work.
The honest reason for the gap is that humans are not big mice. We live sixty times longer, develop diseases in ways mice never do, and possess immune systems that react badly to experimental drugs designed for creatures with radically different biology. A company cannot run the kind of experiment that might settle the question: give people a therapy, then wait forty years to see if they live longer. Instead, researchers measure proxy outcomes like markers of inflammation or epigenetic age. These correlate with aging, but correlation is not proof that extending them will extend life.
The field has matured enough to abandon some fantasies. Cryonics remains pseudoscience. Parabiosis, the transfusion of young blood into old people, produces no lasting benefit. But serious labs continue the grind of understanding aging at the molecular level, knowing that one day the knowledge might matter. Until then, living long still comes down to the boring truths: move your body, eat less, sleep well, and avoid getting hit by a bus.
Published July 6, 2025 · Frisian News · Ljouwert, Fryslân